Thu, Apr 27, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Oxford Investment Partners fund posts positive Q3 +3.6% (+7.1% YTD)

Thursday, October 25, 2012

Bailey McCann, Opalesque New York:

The UK-based Oxford Investment Partners fund released its quarterly earnings letter today noting that overall, it had a positive quarter posting gains of +3.6%, raising the fund to 7.1% for the year. The fund seeks to outperform the global equity index with half the volatility, and half the downside risk. Since 2006, the fund has mostly outperformed the equity markets, save for a blip in 2009, the firm manages just over $7m in assets. From its inception date in May 2006, the fund is up overall +3.5%.

According to the letter, the fund enjoyed an uptick of +11.5 in commodities and +4.6% in US high yield bonds. "The exception was emerging market equities, which continued to underperform developed-economy markets. The yields on government debt in the perceived haven countries of the US, Germany and the UK all rose, though they remained at historically-depressed levels. The yields on Italian and Spanish government debt fell in response to the ECB’s prospective and subsequently announced policy of support," the firm wrote.

Echoing the view of other industry participants the firm writes that the Chinese slowdown has been a cause for disappointment given its once robust pace. Overall, central bank actions continue to dominate the macroeconomic factors influencing the fund portfolio and investor attention, firm principles note. Draghi's willingness to "do whatever it takes," to steer the Eurozone out of its crisis and further easing......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Alternative asset firm YieldStreet surpasses $100m of loans funded in less than 8 quarters[more]

    Komfie Manalo, Opalesque Asia: Alternative asset investment platform YieldStreet reported that it has surpassed $100m in loans funded in less than eight quarters from accredited investors and single family offices. YieldStreet was founded by Milind Mehere and Michael Weisz. In a

  2. Investing - Investor appetite for high-growth IPOs to be tested, Apollo boosts fund's stock allowance for 'diamonds in the rough', Hedge funds uncertain over outlook for Hargreaves Lansdown[more]

    Investor appetite for high-growth IPOs to be tested From FT.com: The US listings market is poised for a busy week with deals that will test investors' appetite for high-growth - but lossmaking - companies. Eight new listings are scheduled for this week, the most since October of 2016,

  3. Hedge funds holding Puerto Rico bonds are looking at a long battle[more]

    Komfie Manalo, Opalesque Asia: Hedge funds which bought Puerto Rico's distressed debt bonds are facing the prospect of a long road ahead to recover their investments as the Caribbean island is attempting to use a U.S. Congress-approved rule that allows it to exploit a bankruptcy-like proceedings

  4. Other Voices: "Winner-take-all" dynamics and hedge fund investing[more]

    A growing stream of thinking in microeconomics is the concept of "winner-take-all" dynamics. The idea seems simple. A combination of networking economics and classic economies of scale creates situations where there are just a few dominant firms or economic agents who are able to capture significant

  5. Investing - How Chipotle's comeback attracted big data robots and value investors alike[more]

    From Forbes.com: When William Ackman's ailing hedge fund Pershing Square Capital Management bet $1 billion on shares in Chipotle Mexican Grill beginning in July 2016, the stakes couldn't have been higher. Pershing Square was reeling from what would eventually be a near $4 billion loss in drugmaker V